By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Sequencing the Insurance Genome
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Health Reform > Sequencing the Insurance Genome
Health ReformMedical InnovationsNewsPolicy & LawPublic Health

Sequencing the Insurance Genome

etwilson
etwilson
Share
4 Min Read
personalized medicine
SHARE

personalized medicineIf you build it, they will come.

The classic Field of Dreams tagline seems to be—perhaps unconsciously—informing the new Precision Medicine Initiative announced by President Obama as he heads into his lame duck period.

personalized medicineIf you build it, they will come.

The classic Field of Dreams tagline seems to be—perhaps unconsciously—informing the new Precision Medicine Initiative announced by President Obama as he heads into his lame duck period.

More Read

Why Ambulatory Surgery Centers Are The Future Of Ambulatory Care
How Clinical Trials Are Changing Cancer Outcomes
FAT FREE = DANGER! (How I hate fat-free half & half)
NCOA Publishes 10 Senior Scams to Beware
How Technology Solutions Are Shaping The Future Of Home Healthcare

Those in the field may recognize this as a next-generation re-branding of personalized medicine, the not-quite-new idea that treatment can be more targeted, more effective, and more personal than current best practices typically entail.

The White House’s Precision program builds on the premise of personalized medicine to specifically target cancer. The multi-million dollar investment is intended to move cancer treatment beyond management—which responds to symptoms and is decidedly reactive—and into prevention. Large-scale genetic sequencing will enable doctors to identify cancer in patients long before they exhibit symptoms, advancing screening to the point that proactive, lifesaving measures become the norm, and a cure is finally feasible.

If—and it is, at this point, still a Mount Everest of an ‘if’—the new initiative succeeds in overcoming all of the scientific, organizational, and practical challenges inherent in this undertaking, there remains a significant policy hurdle that no one involved has yet begun to address: access.

The Affordable Care Act (ACA—or Obamacare, if you prefer) came under fire during its initial implementation for denying patients access to the best cancer treatment hospitals in the country. In fact, this was not so much a feature of the new ACA as it was an integrated failure of the insurance marketplace.

The ACA hinges on getting more Americans covered by health insurance. As the name suggests, this requires many to purchase the most affordable—and therefore limited—coverage available on the new marketplaces. Making these plans affordable requires some cost-cutting on the part of the providers, achieved in part by severely limiting provider networks.

The most modern, cutting-edge hospitals are expensive to add to networks, and so are excluded from many of the entry-level (bronze, in the parlance of the marketplace) or even higher-premium plans (silver and gold).

So even without the next generation of medicine on the table, access to the best treatment available is, at best, extremely limited.

A miracle cure for cancer won’t go far unless the precision screening being developed is provided under more than a minority of hospital networks. More accurate, early screening alone would be worth some celebration. But the President’s allocations also specifically include the FDA, a clear sign that a cure is expected to accompany the genetic risk-analysis being developed.

The ACA failed to stop insurers from top-loading their tiered drug formularies to avoid paying to expensive patients and their treatments. There is no reason to expect that any forthcoming precision cancer drugs will somehow escape this profit-minded tactic.

For personalized care to be truly revolutionary, it needs to do more than take the best elements of scientific knowledge, technology, and virtual connectivity; it needs to be available to the general public who stand to benefit most. With all of the focus on the tech and modernity of personalized care, the importance of the policy challenges seems to be missing—undermining the very significance any potential success the new initiative might have enjoyed.

personalized medicine / shutterstock

Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025
sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025

You Might also Like

Glucometers
News

5 Benefits of Glucometers

March 24, 2022
natural makeup for nontoxic beauty
News

Amazing Health Benefits of Using Natural Makeup for a Wonderful Look

December 1, 2020
cannabis healthy
Health carePublic Health

7 Creative And Practical Ways To Use Cannabis

February 5, 2020

Tobacco Taxes: A Win-Win for the Asia Pacific Region

November 14, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?